Work

FIGURE 3 from A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma

Year: 2024

Type: other

Abstract: (A) NanoString data nSolver normalized log2 counts of DUSP6 pretreatment and on-treatment. B, MAPK signature evaluated at pretreatment and on-treatment using four genes included in the NanoString panel, specifically DUSP6, MYC, TNFAIP3, and PMAIP1. C, GSEA against the Hallmark database; enriched signatures on treatment are depicted in orange, while enriched signatures pretreatment are in blue. D, Enrichment scores of two signatures related to IFN gamma and alpha responses, which are enriched in the on-treatment samples.

DOI: 10.1158/2767-9764.25869063

Authors: Elizabeth I. Buchbinder, Justine V. Cohen, Giuseppe Tarantino, Christine G. Lian, David Liu, Rizwan Haq, F. Stephen Hodi, Donald P. Lawrence, Anita Giobbie-Hurder, Deborah Knoerzer, Ryan J. Sullivan

Language: English

Topic: Ocular Oncology and Treatments

Subfield: Ophthalmology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4398175706

Cites:

Cited by:

Related to: 10